Repligen

RGEN

Market cap $6.83B

Repligen is recovering after a difficult 2024, with Q1 2026 revenue up 15% and 11% organic. Polymem, China, PAT, and the Transformation Office make the story cleaner, but execution still matters.

WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT.

WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate Sustainability Report and related reporting framework disclosures. Themed “Driving Sustainable Growth Together”, this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. Also included in the 2025 Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and three key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB) Standards and the Task Force on Climate-related Financial Disclosures (TCFD), now part of the IFRS Sustainability Alliance.

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada.

RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth. The company raises its 2026 EPS view.

Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript

Repligen (RGEN) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.39 per share a year ago.

WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026.

Class A shares of the Alger Mid Cap Growth Fund underperformed the Russell Midcap Growth Index during the first quarter of 2026. FTAI Aviation Ltd., Vertiv Holdings Co. and Comfort Systems USA, Inc., were among the top contributors to performance. Repligen Corporation, AppLovin Corp., and Carvana Co. were among the top detractors from performance.